StreetAlpha.app
Home › Stocks › SNDX

Syndax Pharmaceuticals Inc (SNDX)

Healthcare
$8.72
▼ −4.49%
LAST CLOSE · NOV 20

Syndax Pharmaceuticals develops and sells cancer medicines, including Revuforj for certain acute leukemias. It last closed at $8.72 on Nov 20, down 4.49% on the day. The next earnings report for SNDX is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, SNDX reported EPS of -$0.55 on revenue of $83.3M, with revenue up 81.6% from a year ago. Over its last 8 reports the stock moved an average of 10.6% the session after earnings. Over the last 12 months SNDX insiders bought $0 of stock on the open market and sold $2.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is SNDX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SNDX.

Key Stats

Last 12 months
Results
Revenue
$289.7M
+160.3% vs a year ago
Net income
−$209.5M
−72.3% margin
EPS (diluted)
−$2.37
Operating margin
−61.7%
−$178.6M operating income
Valuation
Market cap
$778.7M
89.3M shares
P/E
–
No P/E while losing money
Price to sales
2.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$135.9M
At Sep 30
Debt
$594.2M
At Sep 30
Shareholder equity
−$17.2M
Shares outstanding
89.3M
At Jul 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $139.7M$139.7MFY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $23.7M$23.7MFY2024FY2025: $172.4M$172.4MFY2025

From SNDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.55
Quarter ended Sep 2026
Year ago EPS
-$0.70
Same quarter last year
Revenue
$83.3M
+81.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.09Dec '24Mar 2025: -$0.98Mar '25Jun 2025: -$0.83Jun '25Sep 2025: -$0.70Sep '25Dec 2025: -$0.78Dec '25Mar 2026: -$0.48Mar '26Jun 2026: -$0.55Jun '26Sep 2026: -$0.55Sep '26Latest -$0.55
Revenue by quarter
Dec 2024: $7.7MDec '24Mar 2025: $20.0MMar '25Jun 2025: $38.0MJun '25Sep 2025: $45.9MSep '25Dec 2025: $68.7MDec '25Mar 2026: $64.9MMar '26Jun 2026: $72.8MJun '26Sep 2026: $83.3MSep '26Latest $83.3M
How SNDX moved after its last 8 reports
Average move the session after a report ±10.6%
Nov 2, 2026After the close+9.1%
Aug 4, 2026After the close+4.4%
Apr 30, 2026After the close−10.8%
Feb 26, 2026After the close+5.0%
Jan 12, 2026After the close−1.2%
Nov 3, 2025After the close+11.6%
Aug 4, 2025After the close+21.1%
May 5, 2025After the close−21.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SNDXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on SNDX: 0 upgrades, 0 downgrades, 0 initiations
UBS GroupTarget cut
Nov 21  
UBS GroupTarget cut
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on SNDX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SNDX

Technical Analysis

SNDX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 25% below its 20 day and 63% below its 50 day average. It is 123% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $8.52, and the nearest resistance the Pivot at $8.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.7%/day
Key levels
$25.5952 week high+193.5%
$19.43200 day average+122.8%
$17.49100 day average+100.6%
$14.2250 day average+63.1%
$10.9120 day average+25.1%
$9.93Swing high (Nov 12)+13.9%
$9.10Pivot R1+4.4%
$8.89Pivot+1.9%
$8.72Last close
$8.52Pivot S1−2.3%
$8.4152 week low−3.6%
Indicators
RSI (14)27.98Oversold below 30Oversold
MACD-1.64Above its signal lineBullish
Stochastic6.0Near the bottom of its rangeOversold
ADX (14)51.3Strong downtrend
Williams %R-95.1Oversold below −80, overbought above −20Oversold
CCI (20)-70.3Oversold below −100, overbought above 100Neutral
Rate of change−8.6%Change over 10 sessionsBearish
ATR (14)$0.84Typical daily range, 9.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SNDX

What happened before

See how SNDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SNDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SNDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SNDXHow many large options trades hit SNDX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SNDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●111 buying vs 121 selling
  • ▼Held by funds -10.6 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding237242−2.1%
In funds' top 101011−9.1%
Held by funds110.5%121.1%−10.6 pts
New / increased31 / 8034 / 96−14.6%
Reduced / sold out85 / 3675 / 40+5.2%
Put/call ratio0.020.00+2424.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SNDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SNDX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.9M9 sales · 4 insiders
73% of the selling was under pre-arranged trading plans.
2026-02 sold $628K2026-06 sold $1.3M2026-07 sold $785K2026-10 sold $114KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 29Dennis PodlesakDirectorSale plan8,000$14.21$114K
Jul 8Michael A MetzgerCEOSale plan32,375$24.24$785K
Jun 12Nicholas A.J. BotwoodHead of R&D, CMOSale plan65,515$18.07$1.2M
Jun 1Michael A MetzgerCEOSale6,847$18.99$130K
Jun 1Keith A. GoldanCFOSale1,177$18.99$22K
Feb 9Keith A. GoldanCFOSale3,410$21.03$72K
Every insider buy and sale for SNDX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SNDX insider trades →

From SEC Form 4 filings by SNDX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SNDX is in one of them and how their past SNDX trades turned out.

SNDX in the AI portfolios
Loading…

SNDX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SNDX in an article yet. Here's the latest on the wider market.

SNDX in the news

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a biopharmaceutical company based in New York that develops and sells cancer treatments. Its two approved medicines are Revuforj, a pill for certain acute leukemias, and Niktimvo, used to treat chronic graft versus host disease. Syndax leads sales of Revuforj in the United States and works with partner Incyte on Niktimvo. Its customers are cancer patients and the doctors who treat them.

Headquarters
New York, NY